Key Trends and Insights into the Systemic Aspergillosis And Systemic Candidiasis Market: Growth Rate and Opportunities to 2034
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the systemic aspergillosis and systemic candidiasis market size evolved in recent years?
The market size for systemic aspergillosis and systemic candidiasis has shown consistent growth in the past few years. The market is set to increase from a value of $7.24 billion in 2024 to $7.59 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 4.8%. The expansion during the historical phase is due to factors such as the escalating occurrence of fungal infections, higher numbers of patients with compromised immune systems, advancements in diagnostic technologies, an increase in invasive medical procedures, and the worldwide proliferation of infections.
What are the predictions for the systemic aspergillosis and systemic candidiasis market size in the coming years?
The market size for systemic aspergillosis and systemic candidiasis is poised to experience robust growth in the forthcoming years, reaching a valuation of $9.28 billion in 2029, with a compound annual growth rate (CAGR) of 5.1%. This growth during the projected period is due to factors such as international surveillance for antifungal resistance, an increasing elderly population, the use of telemedicine for distant consultations, patient-centered drug development, and digital health solutions for patient care. The forecast period will also see major trends like the development of new fungal biomarkers for early detection, the introduction of innovative antifungal agents, progress in immunotherapy, and the introduction of innovative drug delivery systems.
Get your systemic aspergillosis and systemic candidiasis market report here!
What key factors are fueling the growth of the systemic aspergillosis and systemic candidiasis market?
Rise in fungal diseases is anticipated to stimulate the maturation of the systemic aspergillosis and systemic candidiasis market. Fungal diseases, which refer to the infections triggered by fungi, can influence various body segments, leading to several symptoms and complications. Such diseases encompass cutaneous skin infections, respiratory infections, and systemic infections. Treatments for these fungal diseases include antifungal medications like oral azoles, voriconazole, and liposomal amphotericin B. To illustrate, Lancet, a globally reputable London-based medical journal referenced for health knowledge, reported in July 2024 that each year sees an estimated 6.5 million invasive fungal infection cases and 3.8 million corresponding deaths. Around 2.5 million of these deaths are attributed directly to the infections. Hence, the surge in fungal disease incidence is propelling the expansion of the systemic aspergillosis and systemic candidiasis market.
How is the global systemic aspergillosis and systemic candidiasis market divided into key segments?
The systemic aspergillosis and systemic candidiasis market covered in this report is segmented –
1) By Type: Systemic Oral Azoles, Voriconazole, Liposomal Amphotericin B, Topical Antifungal Agents, Other Types
2) By Application: Allergic Bronchopulmonary Aspergillosis (ABPA), Chronic Pulmonary Aspergillosis (CPA), Gastrointestinal Candidiasis, Genitourinary Tract Candidiasis, Other Applications
3) By End User: Clinic, Hospital, Other End Users
Subsegments:
1) By Systemic Oral Azoles: Fluconazole, Itraconazole, Posaconazole, Voriconazole
2) By Voriconazole: Voriconazole Tablets, Voriconazole Injection
3) By Liposomal Amphotericin B: Liposomal Amphotericin B For Systemic Aspergillosis, Liposomal Amphotericin B For Systemic Candidiasis
4) By Topical Antifungal Agents: Topical Azoles, Topical Polyenes, Topical Allylamines
5) By Other Types: Echinocandins, Antifungal Combination Therapies, Other Emerging Antifungal Agents
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12148&type=smp
Who are the key firms paving the way for growth in the systemic aspergillosis and systemic candidiasis market?
Major companies operating in the systemic aspergillosis and systemic candidiasis market include Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Abbott Laboratories, Sanofi S.A., GlaxoSmithKline PLC, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Matinas BioPharma Holdings Inc., Shionogi & Co. Ltd, Cipla Limited, Taj Pharmaceuticals Limited, Basilea Pharmaceutica Ltd., Cidara Therapeutics Inc., T2 Biosystems Inc., Sandoz International GmbH, Grupo Ferrer International S.A., Entasis Therapeutics Inc., F2G Ltd., Mycovia Pharmaceuticals Inc., ContraFect Corporation, Enzon Pharmaceutical Inc., Pacgen Life Science Corporation, Biosergen AS, N8 Medical LLC
Which trends are expected to transform the systemic aspergillosis and systemic candidiasis market?
Leading corporations in the systemic aspergillosis and systemic candidiasis sectors are focusing their efforts on creating novel products, like echinocandins, to boost effectiveness of treatments and confront the escalating issues of antifungal resistance. Echinocandins, a type of antifungal medication, work by halting the production of β-glucan, a vital part of the fungal cell wall. For example, Cidara Therapeutics and Melinta Therapeutics, both biotech firms based in the US, gained approval in March 2023 from the Food and Drug Administration (FDA), the US federal agency tasked with safeguarding public health, for their product REZZAYO (rezafungin for injection). REZZAYO is a unique echinocandin administered once weekly for treating candidemia in adults who have few or no other treatment alternatives. REZZAYO’s simplified once-weekly dosage regimen enhances treatment consistency and makes administration easier for patients suffering from invasive candidiasis. This is extremely advantageous in hospital situations, where controlling such infections efficiently is crucial.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12148
What regions are contributing significantly to the growth of the systemic aspergillosis and systemic candidiasis market?
North America was the largest region in the systemic aspergillosis and systemic candidiasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the systemic aspergillosis and systemic candidiasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Automobiles And Heavy Equipment Global Market Report 2024
Electric Motor And Generator Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/electric-motor-and-generator-global-market-report
Automotive Light Emitting Diode (LED) Bulbs Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
